Unexpectedly, an official earthquake over the weekend pushed the Ant Group to the cusp of the storm.
Ant Group debunks rumors: It is rumored that relevant personnel have invested in Ant Group on the Internet
Late at night on the 22nd, Ant Group issued a statement on its official WeChat public account.
The statement said that for the false news that the relevant personnel on the Internet "invested in Ant Group", Ant Group refutes rumors that Ant Group strictly abided by the laws and regulations of the two places in the previous IPO issuance process, the process was open and transparent, and there was no relevant personnel mentioned in the rumors, let alone the situation related to surprise shares and refunds.
Ant Group has never engaged in any form of business cooperation with the law firms and lawyers mentioned in the rumors.
On the evening of the 21st, Zhou Jiangyong, secretary of the Hangzhou Municipal Party Committee, was suspected of serious violations of discipline and law and is currently under disciplinary review and supervision and investigation by the State Supervision Commission of the Central Discipline Inspection Commission.
Over the weekend, some self-media published articles saying that in November 2020, the listing plan of a financial technology company in Zhejiang was urgently stopped. Before the IPO, his family spent money to buy shares first. However, at present, the article has been deleted by itself.
Collection and supply cut-off! Not fulfilling corporate responsibility?
North China Pharmaceutical responded
There was another big event on the evening of the 22nd.
Winning the bid for collection and mining, but taking the initiative to give up, North China Pharmaceutical opened a precedent for A-share supply and collection.
On August 20, Shanghai Sunshine Pharmaceutical Procurement Network issued the "Announcement on Including North China Pharmaceutical Co., Ltd. in the List of Violations", and the third batch of selected enterprises in the centralized procurement of drugs from the state to purchase ibuprofen sustained-release capsules failed to supply the agreed procurement volume in Shandong Province, and the supply situation remained unchanged after repeated interviews and consultations with relevant departments.
It is reported that North China Pharmaceutical proposed to give up the qualification for the selection on August 11, 2021, and the relevant medical institutions in Shandong reacted strongly to this.
According to the data, when the third batch of national procurement bidding, the ibuprofen sustained-release capsules of North China Pharmaceutical were selected at a price of 8.04 yuan / box (0.3g * 30 capsules), and obtained the purchase volume of Shandong, Tianjin, Hubei, Hunan and other provinces. The price selected in North China Pharmaceutical is about 0.268 yuan / grain, the highest among the 4 selected enterprises, while the price of Zhuhai Rundu in the takeover is 0.203 yuan / grain.
On the evening of August 22, North China Pharmaceutical issued an announcement to explain the matters that the company was included in the list of violations due to the interruption of collection and supply. The announcement said that after the company's ibuprofen sustained release capsules were selected, due to the company's insufficient existing production capacity, the degree of attention paid insufficient to the responsible units, the relevant registration and change policy adjustments, coupled with the impact of the epidemic, the company could not guarantee normal supply.
In order to minimize the impact on the supply of shandong province, the company communicated with the Shandong Provincial Medical Security Bureau, and the company proposed to give up the qualification for the selection, and Shandong Province invited other enterprises to supplement the bidding for the product. In the next step, the company will accelerate the approval progress of the ibuprofen sustained-release capsule expansion project, strive to complete the approval by the end of September, and the annual production capacity is expected to reach 100 million capsules after the expansion, and fully guarantee the supply of the product in other selected provinces. From January to July this year, the sales revenue of the product was 2.9381 million yuan, which will not have a significant impact on the company's operating performance in the current period.
A person in the pharmaceutical industry told the media that it is a common phenomenon that the supply of drugs cannot keep up after entering the collection. The reason is that the price of APIs has risen due to monopoly or other reasons, resulting in the collection price not being able to cover the cost, and the enterprise is unwilling to lose money and choose to cut off the supply; the other may be that the pharmaceutical company has problems in the production process and needs to transform the production line, resulting in the inability to produce normally and the supply is cut off.